This article provides general legal information, not legal advice. GLP-1 drug claims are fact-specific, deadlines vary by state, and outcomes depend on the medical proof, product used, and law that applies. Consult a licensed attorney in your state about your specific situation.
An Ozempic gastroparesis lawsuit usually begins with a medical problem that does not feel minor. A person starts Ozempic, Wegovy, Rybelsus, Mounjaro, or Zepbound. Then severe nausea, vomiting, stomach pain, dehydration, or a diagnosis such as gastroparesis (delayed stomach emptying), ileus, or bowel obstruction follows. The first question is often medical: is this a known risk, or is something else going on?
The second question is legal. In 2026, gastrointestinal GLP-1 claims are moving through a large federal multidistrict litigation, or MDL. Vision-loss claims tied to NAION are in a separate federal MDL. That split matters because many online pages still blur these cases together. Readers need to know which track may apply, what records matter most, and how quickly they need to act.
This guide explains the Ozempic gastroparesis lawsuit landscape as of April 2026. It covers which GLP-1 drugs are part of the gastrointestinal litigation. It also explains what proof can make a claim stronger and how filing deadlines may work. Readers should be careful with settlement claims that overpromise. Finally, it separates what regulators, court orders, and medical studies say from what is still being disputed.
If you are trying to sort out symptoms, timing, and records, start with the Do I Qualify? assessment . It can help organize the basics before a legal review.
What Is an Ozempic Gastroparesis Lawsuit?
An Ozempic gastroparesis lawsuit is a product-liability claim. It alleges that a GLP-1 receptor agonist caused or contributed to a serious gastrointestinal injury. It also alleges that the drug makers failed to provide adequate warnings or safety information. These claims usually focus on injuries such as gastroparesis, ileus, intestinal obstruction, severe chronic vomiting, or similar digestive complications.
The federal judicial panel that created MDL 3094 described these cases as personal injury actions involving GLP-1 receptor agonists. The order named drugs including Ozempic, Wegovy, Rybelsus, Trulicity, and Mounjaro. It also described allegations that the drugs can cause gastroparesis and other gastrointestinal injuries. See the JPML transfer order for MDL 3094 .
That does not mean every patient with nausea has a case. The practical legal question is narrower. Was there documented use of a covered drug? Was there a documented gastrointestinal injury? Does the timeline plausibly connect the medication to the harm? Depending on the facts, a claimant may seek compensation for medical costs, lost income, pain and suffering, or other losses. No outcome is guaranteed.
What Is Actually Happening in the GLP-1 Lawsuits in 2026?
As of April 1, 2026, the Judicial Panel on Multidistrict Litigation reported 3,546 actions pending in MDL No. 3094, the federal GLP-1 gastrointestinal injury litigation in the Eastern District of Pennsylvania. The same JPML statistics report listed 73 actions pending in MDL No. 3163, the separate GLP-1 vision-loss litigation involving non-arteritic anterior ischemic optic neuropathy, usually called NAION. See the JPML pending MDL statistics report dated April 1, 2026 .
That split is one of the most important facts for readers in 2026. Gastrointestinal injury claims and NAION vision-loss claims are not one combined lawsuit. They are related only in the broad sense that both involve GLP-1 drugs. The court tracks, schedule orders, and proof problems are different.
MDL 3094 is still being shaped by motion practice rather than headline trial dates. Case Management Order No. 23 set a schedule for summary judgment and Rule 702 expert briefing, with replies due May 8, 2026. See MDL 3094 Case Management Order No. 23 . In plain language, the litigation is active, but it is still focused on threshold evidence and expert questions.
Why Are GI Injury Claims and NAION Claims Separate Lawsuits?
The gastrointestinal cases involve allegations about delayed stomach emptying, bowel injury, and severe digestive complications. The NAION cases involve alleged optic-nerve injury and sudden vision loss. Those are different medical mechanisms, different expert fields, and different regulatory questions. That is why the court system split them.
The JPML transfer order for MDL No. 3163 created a separate proceeding for GLP-1 NAION claims in the Eastern District of Pennsylvania. A later schedule order set recurring 2026 status conferences, including dates in February, March, April, May, June, July, October, November, and December. See the JPML transfer order for MDL 3163 and MDL 3163 Schedule Order No. 1 .
For readers, the practical takeaway is simple. If the issue is gastroparesis, ileus, bowel obstruction, or severe chronic GI symptoms, the relevant federal track is the GI MDL. If the issue is diagnosed NAION or similar vision-loss injury, that is a separate federal track. Merging them can make a claim screening conversation less accurate.
Which GLP-1 Drugs Are Included in the Gastrointestinal Litigation?
The best-known brand is Ozempic, but the litigation is broader than one product. The federal GLP-1 GI cases involve branded semaglutide drugs such as Ozempic, Wegovy, and Rybelsus. They also involve tirzepatide drugs such as Mounjaro and Zepbound. The MDL 3094 transfer order also included Trulicity in the broader GLP-1 landscape.
That matters because many people search for an Ozempic gastroparesis lawsuit when they actually used Wegovy, Rybelsus, Mounjaro, or Zepbound. The legal question is usually not whether the brand name in a headline matches perfectly. It is whether the claimant used a drug that fits the relevant litigation and can document the use.
It is also important not to confuse branded drugs with compounded or unapproved copies. FDA warns that unapproved GLP-1 products do not undergo FDA review for safety, effectiveness, and quality before marketing. That includes some compounded versions of semaglutide and tirzepatide. See FDA’s guidance on unapproved GLP-1 drugs used for weight loss . Depending on circumstances, litigation involving compounded products could raise different proof and defendant-identification issues.
What Is Gastroparesis and Why Are Plaintiffs Suing?
Gastroparesis means the stomach empties more slowly than it should. The result can feel like food is just sitting there. People may experience severe nausea, vomiting, bloating, abdominal pain, dehydration, malnutrition, constipation, or repeated emergency visits. In more serious situations, doctors may document ileus or bowel obstruction issues instead of a straight gastroparesis diagnosis.
The lawsuit theory is not built on symptoms alone. It is built on allegations that GLP-1 drugs can slow gastric emptying. Plaintiffs also allege that some patients experienced serious GI injuries after use. They say the warnings and risk disclosures are being contested in court. The 2024 JPML transfer order itself noted that GLP-1 drugs slow gastric emptying. The current prescribing information for Ozempic says the drug has been associated with severe gastrointestinal adverse reactions. It also says Ozempic is not recommended in patients with severe gastroparesis. See the Ozempic prescribing information .
The current Mounjaro label uses similar language. It states that use has been associated with severe gastrointestinal adverse reactions. It also says Mounjaro is not recommended in patients with severe gastroparesis. See the Mounjaro prescribing information . That does not end the causation debate, but it does show why GI injury claims are being litigated seriously.
Who May Qualify for an Ozempic Gastroparesis Lawsuit?
A claimant may potentially qualify if there is documented use of a relevant branded GLP-1 drug. There also needs to be a diagnosed gastrointestinal injury or a persistent symptom pattern consistent with gastroparesis or obstruction. A plausible timeline between the medication and the injury matters too. Stronger cases usually involve treatment records rather than memory alone.
Examples of facts that can strengthen a screening review include a gastric emptying study and GI specialist notes. Endoscopy findings showing retained gastric contents can help too. Emergency room records for dehydration or severe vomiting can also matter. So can hospital admissions, discontinuation notes, and prescription records showing which drug was actually used. A claim usually gets weaker when the symptoms were brief, never evaluated, or are hard to separate from other medical explanations.
Ordinary temporary nausea is not the same thing as a viable mass-tort claim. The court’s focus on expert proof and diagnostic standards means that objective testing and careful timelines matter. A person may still have a claim without one perfect test result. Still, the claim is usually easier to evaluate when the medical workup is stronger.
What Medical Evidence Makes an Ozempic Claim Stronger?
Think of an Ozempic gastroparesis claim like building a bridge between drug use and injury. One side of the bridge is proof of exposure. The other side is proof of injury. The middle is timing, medical evaluation, and alternative-cause analysis.
Useful records often include pharmacy records, prescription packaging, dosage history, primary-care notes, and GI consultation notes. Gastric emptying studies, endoscopy results, emergency department records, anti-nausea medication history, and notes about symptoms after stopping the drug may also help. If vision loss is also involved, that should usually be screened separately because NAION now sits in a different MDL track.
The medical literature is not one-sided. A 2023 JAMA claims-data study reported increased risk of gastroparesis and bowel obstruction among GLP-1 agonist users for weight loss. The comparison group used bupropion-naltrexone. A 2025 systematic review and meta-analysis did not find a clear increase across every gastrointestinal outcome. See the JAMA study on gastrointestinal adverse events and the 2025 PubMed-listed systematic review . That is why careful legal writing should use words like associated, alleged, and being litigated. The issue should not be described as medically settled.
What Do Regulators Say About Gastroparesis and Vision Loss?
The current U.S. labels for Ozempic and Mounjaro say the drugs are not recommended in patients with severe gastroparesis. Both labels also discuss severe gastrointestinal adverse reactions. That does not automatically resolve failure-to-warn claims. It is still a meaningful regulatory fact for readers who are trying to understand why GI cases exist.
Vision-loss claims require more nuance. Current official materials cited in this guide do not show a clear U.S. FDA semaglutide label warning specifically naming NAION. But the European Medicines Agency announced on June 6, 2025, that its safety committee reached a different view. It concluded NAION is a very rare side effect of semaglutide medicines and recommended product-information updates. See the EMA PRAC announcement on semaglutide and NAION .
That difference between U.S. and European regulatory posture is one reason the NAION cases should be analyzed separately. It also shows why readers should be cautious. Not every GLP-1 injury theory sits on the same factual footing.
What Are the Filing Deadlines for an Ozempic Lawsuit?
The filing deadline is called the statute of limitations, which is the deadline to file suit. Drug-injury deadlines vary by state, and pharmaceutical cases often involve disputes about accrual, discovery, wrongful-death timing, and statutes of repose. That means there is no single national deadline for an Ozempic gastroparesis lawsuit.
Three examples show why state law matters. California Code of Civil Procedure section 335.1 generally provides two years for injury or death caused by the wrongful act or neglect of another, while California Code of Civil Procedure section 340.8 contains discovery-rule language for some hazardous-material or toxic-substance injury cases. See California CCP 335.1 and California CCP 340.8 . New York CPLR 214-c provides a three-year discovery rule for certain latent injuries caused by exposure to a substance. See New York CPLR 214-c . Pennsylvania’s general two-year limitation appears in 42 Pa. Cons. Stat. section 5524. See 42 Pa. Cons. Stat. section 5524 .
Those examples are not a substitute for legal advice. The correct deadline can change based on the state, the injury date, and the diagnosis date. It can also depend on the type of claim and when a reasonable person should have connected the injury to the drug. Consult a licensed attorney in your state promptly. Some states are less forgiving than others. Waiting can destroy a claim before anyone reaches the merits.
What Compensation Could Potentially Be Available?
No one can honestly promise a settlement amount in the current GI MDL. The litigation is still focused on expert challenges, warning issues, and case screening. Articles that jump straight to payout numbers often leave out the harder truth. Case value follows proof, jurisdiction, injury severity, and the litigation track the claim actually fits.
Depending on the facts, a successful claimant may seek damages for past and future medical bills. Other damages may include lost wages or reduced earning capacity, pain and suffering, and in wrongful-death cases, losses available under state law. Compensation could vary sharply between patients. A case with documented hospitalizations and objective testing is different from a case with temporary symptoms that were never fully evaluated.
If you are unsure where your records point, start with the basics. The issue may fit the GI MDL, the NAION MDL, or no viable claim. The Do I Qualify? assessment can help separate the basic facts before you speak with counsel.
How Do You File an Ozempic Gastroparesis Claim?
Filing usually starts with records, not slogans. The first step is to gather proof of which drug was used and when it was prescribed. It also helps to confirm whether the product was branded Ozempic, Wegovy, Rybelsus, Mounjaro, or Zepbound rather than an unapproved copy. The second step is to collect the medical records that show what happened next.
- Save pharmacy records, prescription labels, refill history, and any documentation showing the exact GLP-1 drug used.
- Request GI specialist records, gastric emptying studies, hospital discharge summaries, emergency records, and notes about dehydration, vomiting, or obstruction.
- Build a simple timeline showing when the medication began, when symptoms began, when the drug was stopped, and what treatment followed.
- Get a state-specific limitations review early, especially if the injury happened months or years ago.
- If the problem is vision loss rather than GI injury, screen that separately. The NAION cases now sit in MDL 3163, not MDL 3094.
What You Can Do Right Now
If you are trying to figure out whether a GLP-1 injury may support a legal claim, start with the facts. Focus on what you can control.
- Identify the exact drug used and whether it was a branded product or a compounded or unapproved copy.
- Write down the month the drug started, the month symptoms started, and the dates of the most important hospital or specialist visits.
- Preserve objective testing and discharge paperwork, because serious GI cases are being screened carefully.
- Do not assume that online settlement estimates apply to your case.
- If you want a fast intake path while collecting records, use the Do I Qualify? assessment to organize the basics before a deeper case review.
FAQ: Ozempic Gastroparesis Lawsuit Questions
Can Ozempic cause gastroparesis or stomach paralysis?
That is being actively litigated. The current labels acknowledge severe gastrointestinal reactions and say the drug is not recommended in patients with severe gastroparesis. They do not, by themselves, resolve legal causation. That still depends on the individual medical record, timing, and competing explanations.
Who qualifies for an Ozempic stomach paralysis claim?
Usually a claimant needs documented use of a relevant GLP-1 drug. The file should also show serious GI symptoms or diagnosis and records that make the timeline medically plausible. Objective testing and specialist workup usually help.
Is there a separate Ozempic lawsuit for vision loss or NAION?
Yes. As of 2026, NAION claims are being handled in a separate federal MDL, MDL 3163. They are not part of the main gastrointestinal injury MDL 3094.
Which drugs are included besides Ozempic?
Readers often mean semaglutide and tirzepatide products more broadly. The GI litigation has included products such as Ozempic, Wegovy, Rybelsus, Mounjaro, and related GLP-1 drugs identified in the federal orders.
How long do I have to file an Ozempic lawsuit?
It depends on state law and accrual rules. Many states use a two-year personal injury period, but discovery rules, repose issues, and wrongful-death rules can change the answer. Early legal review matters.
Conclusion
The Ozempic gastroparesis lawsuit landscape in 2026 is real, active, and more complicated than many lead-generation pages suggest. The key facts are simple. Gastrointestinal injury claims are moving through MDL 3094. NAION vision-loss claims are in separate MDL 3163. The strongest cases usually depend on documented drug use, documented injury, and documented timing.
If you believe a GLP-1 drug may have caused serious digestive injury, organize your records before more time passes. Use the Do I Qualify? assessment to review your product history, symptoms, and timing in one place.
This article provides general legal information, not legal advice. GLP-1 injury claims, deadlines, and available compensation depend on the facts, the product used, medical proof, and state law. For advice about your situation, consult a licensed attorney in your state.